Targets › CDA
1 program from 1 company in 2 trials: 1 Phase 2, 1 Phase 1; Hematology, Oncology; next expected readout Nov 2027.
This enzyme scavenges exogenous and endogenous cytidine and 2'-deoxycytidine for UMP synthesis. (UniProt, P32320)
Open in Phaseline: the race on CDA, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Taiho Oncology | Cedazuridine Cytidine deaminase inhibitor | CDA | Phase 2 | Myelodysplastic Syndromes; Solid Tumor | Nov 2027 |
Myelodysplastic Syndromes (1) Solid Tumor (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.